A study of Rivastigmine (Multiday Transdermal Patch) the treatment of Alzheimer's disease.

Trial Profile

A study of Rivastigmine (Multiday Transdermal Patch) the treatment of Alzheimer's disease.

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Mar 2017 According to a Luye Pharma media release, the Federal Institute for Drugs and Medical Devices in Germany (the German health authority) granted approval to commence clinical trials for Rivastigmine Multiday Transdermal Patch (Rivastigmine MD) for the treatment of Alzheimer's disease.
    • 09 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top